Cargando…
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy (busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such as imatinib. Although imatinib has profoundly improved outcomes for patients with CML, it has limitations. Most significantly, ima...
Autores principales: | Talpaz, M, Hehlmann, R, Quintás-Cardama, A, Mercer, J, Cortes, J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703612/ https://www.ncbi.nlm.nih.gov/pubmed/23238589 http://dx.doi.org/10.1038/leu.2012.313 |
Ejemplares similares
-
Chronic Myeloid Leukemia in 2020
por: Hehlmann, Rüdiger
Publicado: (2020) -
Dasatinib dose management for the treatment of chronic myeloid leukemia
por: Talpaz, Moshe, et al.
Publicado: (2018) -
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
por: Hehlmann, Rüdiger, et al.
Publicado: (2022) -
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
por: Hughes, T P, et al.
Publicado: (2015) -
Prognostic Impact of the MDM2(SNP309) Allele in Leukemia and Lymphoma
por: Post, Sean M., et al.
Publicado: (2010)